Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The effect of colchicine in patients with COVID-19
IRCT20251112067972N1Phase 3Completed
- Sponsor
- vice chancellor for research and technology
- Start
- Jan 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of colchicine in coronavirus disease 2019 (COVID-19), sponsored by vice chancellor for research and technology. Started Jan 2026; status: completed.
02
Drugs
colchicine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20251112067972N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251112067972N1.